CH680650A5 - - Google Patents

Download PDF

Info

Publication number: CH680650A5
Authority: CH; Switzerland
Prior art keywords: components; fatty acid; weight; cyclosporin; acid
Prior art date: 1989-02-20

Application number

CH504/90A

Other languages

German (de)

English (en)

Inventor

Ulrich Dr Posanski

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-20

Filing date

1990-02-16

Publication date

1992-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10651981&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CH680650(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-02-16 Application filed by Sandoz Ag filed Critical Sandoz Ag

1992-10-15 Publication of CH680650A5 publication Critical patent/CH680650A5/de

Links

239000000203 mixture Substances 0.000 claims description 102
229960001265 ciclosporin Drugs 0.000 claims description 99
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 91
108010036949 Cyclosporine Proteins 0.000 claims description 89
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 80
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 73
229930182912 cyclosporin Natural products 0.000 claims description 73
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 68
239000000194 fatty acid Substances 0.000 claims description 68
235000014113 dietary fatty acids Nutrition 0.000 claims description 65
229930195729 fatty acid Natural products 0.000 claims description 65
239000000047 product Substances 0.000 claims description 56
-1 fatty acid ester Chemical class 0.000 claims description 50
229930105110 Cyclosporin A Natural products 0.000 claims description 49
150000004665 fatty acids Chemical class 0.000 claims description 41
235000011187 glycerol Nutrition 0.000 claims description 28
239000000470 constituent Substances 0.000 claims description 24
239000002253 acid Substances 0.000 claims description 23
238000005809 transesterification reaction Methods 0.000 claims description 23
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 21
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 21
239000000600 sorbitol Substances 0.000 claims description 21
235000015112 vegetable and seed oil Nutrition 0.000 claims description 21
239000008158 vegetable oil Substances 0.000 claims description 21
150000002148 esters Chemical class 0.000 claims description 19
239000004094 surface-active agent Substances 0.000 claims description 18
230000036961 partial effect Effects 0.000 claims description 15
239000008194 pharmaceutical composition Substances 0.000 claims description 15
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 12
239000004480 active ingredient Substances 0.000 claims description 8
239000004359 castor oil Substances 0.000 claims description 7
235000019438 castor oil Nutrition 0.000 claims description 6
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 4
229920001214 Polysorbate 60 Polymers 0.000 claims description 3
239000007795 chemical reaction product Substances 0.000 claims description 3
WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 claims description 2
229920001400 block copolymer Polymers 0.000 claims description 2
KWABLUYIOFEZOY-UHFFFAOYSA-N dioctyl butanedioate Chemical compound CCCCCCCCOC(=O)CCC(=O)OCCCCCCCC KWABLUYIOFEZOY-UHFFFAOYSA-N 0.000 claims description 2
150000003904 phospholipids Chemical class 0.000 claims description 2
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
108010036941 Cyclosporins Proteins 0.000 description 24
210000004369 blood Anatomy 0.000 description 19
239000008280 blood Substances 0.000 description 19
238000007127 saponification reaction Methods 0.000 description 19
239000003921 oil Substances 0.000 description 18
235000019198 oils Nutrition 0.000 description 18
238000002560 therapeutic procedure Methods 0.000 description 16
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 14
239000011630 iodine Substances 0.000 description 14
229910052740 iodine Inorganic materials 0.000 description 14
239000002285 corn oil Substances 0.000 description 13
235000005687 corn oil Nutrition 0.000 description 13
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 13
239000002904 solvent Substances 0.000 description 13
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 12
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 12
238000012360 testing method Methods 0.000 description 12
235000021355 Stearic acid Nutrition 0.000 description 11
239000002609 medium Substances 0.000 description 11
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 11
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 11
239000008117 stearic acid Substances 0.000 description 11
150000003626 triacylglycerols Chemical class 0.000 description 11
210000002966 serum Anatomy 0.000 description 10
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 9
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 9
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 9
239000005642 Oleic acid Substances 0.000 description 9
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 9
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 9
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 9
235000021313 oleic acid Nutrition 0.000 description 9
229920006395 saturated elastomer Polymers 0.000 description 9
239000000243 solution Substances 0.000 description 9
239000002552 dosage form Substances 0.000 description 8
230000035622 drinking Effects 0.000 description 8
239000007903 gelatin capsule Substances 0.000 description 8
238000000034 method Methods 0.000 description 8
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 7
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 7
125000004432 carbon atom Chemical group C* 0.000 description 7
239000003814 drug Substances 0.000 description 7
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
229910001868 water Inorganic materials 0.000 description 7
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 6
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 6
235000021314 Palmitic acid Nutrition 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000000787 lecithin Substances 0.000 description 6
235000010445 lecithin Nutrition 0.000 description 6
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 6
229960002446 octanoic acid Drugs 0.000 description 6
239000003381 stabilizer Substances 0.000 description 6
208000023275 Autoimmune disease Diseases 0.000 description 5
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 5
206010029164 Nephrotic syndrome Diseases 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 5
235000020661 alpha-linolenic acid Nutrition 0.000 description 5
239000006184 cosolvent Substances 0.000 description 5
150000005690 diesters Chemical class 0.000 description 5
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
235000020778 linoleic acid Nutrition 0.000 description 5
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 5
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 5
229960004488 linolenic acid Drugs 0.000 description 5
230000000704 physical effect Effects 0.000 description 5
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 4
101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
230000000694 effects Effects 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
238000009472 formulation Methods 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
125000005456 glyceride group Chemical group 0.000 description 4
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
239000006186 oral dosage form Substances 0.000 description 4
238000007911 parenteral administration Methods 0.000 description 4
239000008389 polyethoxylated castor oil Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
239000002562 thickening agent Substances 0.000 description 4
238000011282 treatment Methods 0.000 description 4
235000021122 unsaturated fatty acids Nutrition 0.000 description 4
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
235000010469 Glycine max Nutrition 0.000 description 3
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
239000003240 coconut oil Substances 0.000 description 3
235000019864 coconut oil Nutrition 0.000 description 3
229940109239 creatinine Drugs 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000004006 olive oil Substances 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
229920001993 poloxamer 188 Polymers 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000003860 storage Methods 0.000 description 3
150000004670 unsaturated fatty acids Chemical class 0.000 description 3
GEUKOOCPPICVTB-SMOCYEBVSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s)-33-[(1r,2r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32- Chemical compound CCCC[C@@H](C)[C@@H](O)C1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O GEUKOOCPPICVTB-SMOCYEBVSA-N 0.000 description 2
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
235000019489 Almond oil Nutrition 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
244000060011 Cocos nucifera Species 0.000 description 2
235000013162 Cocos nucifera Nutrition 0.000 description 2
241001440269 Cutina Species 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
239000005639 Lauric acid Substances 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
239000008168 almond oil Substances 0.000 description 2
239000010775 animal oil Substances 0.000 description 2
230000002141 anti-parasite Effects 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
239000003613 bile acid Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
108010040781 dihydrocyclosporin D Proteins 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 2
239000003979 granulating agent Substances 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000002650 immunosuppressive therapy Methods 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
230000003589 nefrotoxic effect Effects 0.000 description 2
231100000381 nephrotoxic Toxicity 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
229940063122 sandimmune Drugs 0.000 description 2
235000003441 saturated fatty acids Nutrition 0.000 description 2
150000004671 saturated fatty acids Chemical class 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
AHQFCPOIMVMDEZ-UNISNWAASA-N (e,2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid Chemical group CN[C@H](C(O)=O)[C@H](O)[C@H](C)C\C=C\C AHQFCPOIMVMDEZ-UNISNWAASA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
WITKSCOBOCOGSC-UHFFFAOYSA-N 2-dodecanoyloxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCC WITKSCOBOCOGSC-UHFFFAOYSA-N 0.000 description 1
SZQACQUAVJHTKK-UHFFFAOYSA-N 2-hydroxyacetic acid;octadecanoic acid Chemical compound OCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O SZQACQUAVJHTKK-UHFFFAOYSA-N 0.000 description 1
BJRXGOFKVBOFCO-UHFFFAOYSA-N 2-hydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(C)O BJRXGOFKVBOFCO-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
108010082126 Alanine transaminase Proteins 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
241001550224 Apha Species 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
241000273930 Brevoortia tyrannus Species 0.000 description 1
241000251730 Chondrichthyes Species 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
208000023661 Haematological disease Diseases 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000772415 Neovison vison Species 0.000 description 1
241000219925 Oenothera Species 0.000 description 1
235000004496 Oenothera biennis Nutrition 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
240000006711 Pistacia vera Species 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920001219 Polysorbate 40 Polymers 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
244000028344 Primula vulgaris Species 0.000 description 1
235000016311 Primula vulgaris Nutrition 0.000 description 1
244000018633 Prunus armeniaca Species 0.000 description 1
235000009827 Prunus armeniaca Nutrition 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
235000019485 Safflower oil Nutrition 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
240000006394 Sorghum bicolor Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
238000008050 Total Bilirubin Reagent Methods 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
235000009754 Vitis X bourquina Nutrition 0.000 description 1
235000012333 Vitis X labruscana Nutrition 0.000 description 1
240000006365 Vitis vinifera Species 0.000 description 1
235000014787 Vitis vinifera Nutrition 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
239000003904 antiprotozoal agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
239000008163 avocado oil Substances 0.000 description 1
239000010480 babassu oil Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000011162 core material Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
108010019249 cyclosporin G Proteins 0.000 description 1
108010019251 cyclosporin H Proteins 0.000 description 1
PWEOPMBMTXREGV-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O PWEOPMBMTXREGV-UHFFFAOYSA-N 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
238000001514 detection method Methods 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
239000010475 evening primrose oil Substances 0.000 description 1
230000029142 excretion Effects 0.000 description 1
229940013317 fish oils Drugs 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
230000034659 glycolysis Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000008169 grapeseed oil Substances 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000011835 investigation Methods 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000036473 myasthenia Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000002547 new drug Substances 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
238000002103 osmometry Methods 0.000 description 1
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229940044519 poloxamer 188 Drugs 0.000 description 1
229920001281 polyalkylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
235000005713 safflower oil Nutrition 0.000 description 1
239000003813 safflower oil Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000523 sample Substances 0.000 description 1
210000003752 saphenous vein Anatomy 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000000779 smoke Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
239000001589 sorbitan tristearate Substances 0.000 description 1
235000011078 sorbitan tristearate Nutrition 0.000 description 1
229960004129 sorbitan tristearate Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229940045136 urea Drugs 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000010497 wheat germ oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CH504/90A 1989-02-20 1990-02-16 CH680650A5 (it)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB898903804A GB8903804D0 (en)	1989-02-20	1989-02-20	Improvements in or relating to organic compounds

Publications (1)

Publication Number	Publication Date
CH680650A5 true CH680650A5 (it)	1992-10-15

Family

ID=10651981

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH504/90A CH680650A5 (it)	1989-02-20	1990-02-16

Country Status (9)

Country	Link
JP (1)	JPH0611703B2 (it)
BE (1)	BE1005236A3 (it)
CH (1)	CH680650A5 (it)
CY (1)	CY1886A (it)
DE (1)	DE4005190A1 (it)
FR (1)	FR2643262B1 (it)
GB (2)	GB8903804D0 (it)
HK (1)	HK149595A (it)
IT (1)	IT1240765B (it)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5639724A (en)	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
GB8904182D0 (en) *	1989-02-23	1989-04-05	Glaxo Canada	Pharmaceutical compositions
HU208491B (en) *	1990-11-27	1993-11-29	Gyogyszerkutato Intezet	Process for producing oral pharmaceutical composition containing cyclosporin
AU688920B2 (en) *	1991-06-27	1998-03-19	Novartis Ag	Transesterified corn oil products
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
IL102236A0 (en) *	1991-06-27	1993-01-14	Ltt Inst Co Ltd	Topical preparations containing cyclosporin
GB9113872D0 (en) *	1991-06-27	1991-08-14	Sandoz Ag	Improvements in or relating to organic compounds
ES2098739T3 (es)	1992-05-13	1997-05-01	Sandoz Ltd	Composiciones oftalmicas conteniendo una cyclosporin.
US5759566A (en) *	1992-07-28	1998-06-02	Poli Industria Chimica Spa	Microemulsion pharmaceutical compositions for the delivery of pharmaceutically active agents
EP0589843B1 (en) *	1992-09-25	2001-11-28	Novartis AG	Pharmaceutical compositions containing cyclosporins
DK0697881T3 (da) †	1993-04-20	2002-10-07	Novartis Ag	Nye farmaceutiske præparater til oral indgivelse indeholdende cyclosporin
DE4412201A1 (de) *	1993-04-20	1994-11-10	Rentschler Arzneimittel	Neue pharmazeutische Zubereitungen zur oralen Verabreichung enthaltend Cyclosporin
NZ247516A (en) *	1993-04-28	1995-02-24	Bernard Charles Sherman	Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
DE4322826A1 (de) *	1993-07-08	1995-01-12	Galenik Labor Freiburg Gmbh	Pharmazeutisches Präparat
DE4340781C3 (de) *	1993-11-30	2000-01-27	Novartis Ag	Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
US5891846A (en) *	1994-02-17	1999-04-06	Shiseido Company, Ltd.	Cyclosporin-containing emulsion composition
EP0694308A4 (en) *	1994-02-17	1997-09-10	Shiseido Co Ltd	CYCLOSPORIN EMULSION COMPOSITION
GB9405304D0 (en) *	1994-03-16	1994-04-27	Scherer Ltd R P	Delivery systems for hydrophobic drugs
US5474979A (en) *	1994-05-17	1995-12-12	Allergan, Inc.	Nonirritating emulsions for sensitive tissue
ES2177652T3 (es)	1994-11-03	2002-12-16	Novartis Ag	Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion.
US5603951A (en) *	1994-11-09	1997-02-18	Hanmi Pharm. Ind. Co., Ltd.	Cyclosporin-containing soft capsule compositions
KR0167613B1 (ko) *	1994-12-28	1999-01-15	한스 루돌프 하우스, 니콜 케르커	사이클로스포린-함유 연질캅셀제 조성물
US5766629A (en) *	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
US5834017A (en) *	1995-08-25	1998-11-10	Sangstat Medical Corporation	Oral cyclopsporin formulations
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
US5827822A (en) *	1996-03-25	1998-10-27	Sangstat Medical Corporation	Cyclosporin a formulations as nanoparticles
DE19544507B4 (de)	1995-11-29	2007-11-15	Novartis Ag	Cyclosporin enthaltende Präparate
CZ288631B6 (cs) *	1996-01-18	2001-08-15	Galena, A. S.	Léčivé přípravky s obsahem cyklosporinu
US5858401A (en) *	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
RU2211047C2 (ru)	1997-01-30	2003-08-27	Новартис Аг	Желатиновые капсулы с твердым покрытием, включающие фармацевтические композиции, практически не содержащие масел
ATE286403T1 (de) *	1997-03-12	2005-01-15	Abbott Lab	Hydrophile binäre systeme zur verabreichung von cyclosporin
WO1998040051A1 (en) *	1997-03-12	1998-09-17	Abbott Laboratories	Lipophilic binary systems for the administration of lipophilic compounds
JP5005847B2 (ja)	1997-07-29	2012-08-22	ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	親油性化合物用の自己乳化性処方
CA2294033C (en)	1997-07-29	2007-01-09	Pharmacia & Upjohn Company	Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
US6008191A (en) *	1997-09-08	1999-12-28	Panacea Biotec Limited	Pharmaceutical compositions containing cyclosporin
US6187747B1 (en)	1997-09-08	2001-02-13	Panacea Biotech Limited	Pharmaceutical composition comprising cyclosporin
US6346511B1 (en)	1997-09-08	2002-02-12	Panacea Biotec Limited	Pharmaceutical composition comprising cyclosporin
US5981607A (en) *	1998-01-20	1999-11-09	Allergan	Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
ID25908A (id) *	1998-03-06	2000-11-09	Novartis Ag	Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
DE19859910C2 (de) *	1998-12-23	2001-03-22	Ratiopharm Gmbh	Orales Arzneimittel
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9912476D0 (en)	1999-05-28	1999-07-28	Novartis Ag	Organic compounds
WO2001032143A1 (en) *	1999-11-02	2001-05-10	Cipla Ltd.	A pharmaceutical composition for the administration of water-insoluble pharmaceutically active substances and a process for preparation thereof
GB2362573A (en) *	2000-05-25	2001-11-28	Cipla Ltd	Cyclosporin formulation
EP1151755B1 (en) *	2000-05-04	2005-03-16	Panacea Biotec Limited	Pharmaceutical compositions comprising cyclosporin as active ingredient
DE10030378A1 (de) *	2000-06-21	2002-03-14	Audit Inst For Medical Service	Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen
US6979672B2 (en)	2002-12-20	2005-12-27	Polichem, S.A.	Cyclosporin-based pharmaceutical compositions
JP4381037B2 (ja)	2003-06-04	2009-12-09	花王株式会社	油脂組成物
US8673351B2 (en)	2005-03-21	2014-03-18	Ivax Pharmaceuticals S.R.O.	Crystallization inhibitor and its use in gelatin capsules
US8492369B2 (en)	2010-04-12	2013-07-23	Clarus Therapeutics Inc	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
JP5887044B2 (ja)	2005-04-15	2016-03-16	クラルスセラピューティクス, インコーポレーテッドClarus Therapeutic, Inc.	疎水性薬物のドラッグデリバリーシステムとその組成物
FR2914188B1 (fr) *	2007-03-28	2012-06-22	Trophos	Nouvelle composition a base d'oxime de cholest-4-en-3-one
GB2451811A (en)	2007-08-09	2009-02-18	Ems Sa	Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
CA2690490C (en) *	2010-01-19	2012-06-26	Accucaps Industries Limited	Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
WO2015108045A1 (ja) *	2014-01-16	2015-07-23	マルホ株式会社	経皮投与用外用剤
WO2016033556A1 (en)	2014-08-28	2016-03-03	Lipocine Inc.	BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en)	2014-08-28	2016-03-03	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
EP3544614A4 (en)	2016-11-28	2020-08-05	Lipocine Inc.	ORAL TESTOSTERONE UNDECANOATE THERAPY
AU2019308326A1 (en)	2018-07-20	2021-03-18	Lipocine Inc.	Liver disease
CA3136485A1 (en)	2019-04-11	2020-10-15	R.P. Scherer Technologies, Llc	Formulation for oral delivery of proteins, peptides and small molecules with poor permeability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI65914C (fi) *	1978-03-07	1984-08-10	Sandoz Ag	Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
CH641356A5 (en) *	1979-02-27	1984-02-29	Sandoz Ag	Pharmaceutical compositions containing cyclosporin
AU558155B2 (en) *	1982-02-01	1987-01-22	Sandoz Ltd.	Treating multiple sclerosis with dihydro-cyclosporin d

1989
- 1989-02-20 GB GB898903804A patent/GB8903804D0/en active Pending
1990
- 1990-02-16 CH CH504/90A patent/CH680650A5/de not_active IP Right Cessation
- 1990-02-16 GB GB9003616A patent/GB2228198B/en not_active Expired - Lifetime
- 1990-02-19 DE DE4005190A patent/DE4005190A1/de not_active Ceased
- 1990-02-19 BE BE9000181A patent/BE1005236A3/fr not_active IP Right Cessation
- 1990-02-19 JP JP2038168A patent/JPH0611703B2/ja not_active Expired - Lifetime
- 1990-02-19 FR FR9002086A patent/FR2643262B1/fr not_active Expired - Lifetime
- 1990-02-20 IT IT47650A patent/IT1240765B/it active IP Right Grant
1995
- 1995-09-21 HK HK149595A patent/HK149595A/xx not_active IP Right Cessation
1996
- 1996-04-05 CY CY188696A patent/CY1886A/xx unknown

Also Published As

Publication number	Publication date
FR2643262B1 (fr)	1993-06-11
GB9003616D0 (en)	1990-04-11
GB2228198A (en)	1990-08-22
HK149595A (en)	1995-09-29
CY1886A (en)	1996-04-05
DE4005190A1 (de)	1990-08-23
GB2228198B (en)	1992-12-16
IT9047650A1 (it)	1990-08-21
JPH0611703B2 (ja)	1994-02-16
BE1005236A3 (fr)	1993-06-08
IT9047650A0 (it)	1990-02-20
JPH02255623A (ja)	1990-10-16
GB8903804D0 (en)	1989-04-05
IT1240765B (it)	1993-12-17
FR2643262A1 (fr)	1990-08-24

Publication	Publication Date	Title
CH680650A5 (it)	1992-10-15
DE4219526C2 (de)	1999-04-22	Pharmazeutisches Mittel
AT404552B (de)	1998-12-28	Neue cyclosporin enthaltende galenische formulierungen
DE3930928C2 (de)	1994-06-01	Cyclosporin enthaltende pharmazeutische Formulierungen
DE69631601T2 (de)	2004-12-16	Pharmazeutische zusammensetzungen von cyclosporine mit einer polyethoxylierten hydroxy-fettsaäure
DE69816335T2 (de)	2004-04-15	Cyclosporin-enthaltende mikroemulsion-vorkonzentratzusammensetzung
DE4340781C3 (de)	2000-01-27	Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
DE4332436B4 (de)	2007-04-26	Cyclosporin enthaltende pharmazeutische Zusammensetzungen
DE69734253T2 (de)	2006-07-06	Arzneizusammensetzungen enthaltend Rapamycinderivate
AT403163B (de)	1997-11-25	Neue kristallform von ciclosporin, verfahren zu ihrer herstellung, diese kristallform enthaltende pharmazeutische zusammensetzung und verwendung dieser kristallform
DD142149A5 (de)	1980-06-11	Verfahren zur herstellung resorbierbarer galenischer kompositionen
DE69723671T2 (de)	2004-04-22	Cyclosüporin formulierung
DE69711267T2 (de)	2002-11-21	Cyclosporin enthaltende Weichkapselpräparate
CH683672A5 (de)	1994-04-29	Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe.
DE69921409T2 (de)	2006-03-09	Cyclosporin enthaltende Zusammensetzungen
EP0697881A1 (de)	1996-02-28	Neue pharmazeutische zubereitungen zur oralen verabreichung enthaltend cyclosporin
DE60018715T2 (de)	2006-04-27	Pharmazeutische Zusammensetzung enthaltend Cyclosprin als aktiven Bestandteil
AT409082B (de)	2002-05-27	Pharmazeutische orale zusammensetzung enthaltend fk506
KR100256007B1 (ko)	2000-05-01	사이클로스포린을 함유하는 약학 조성물
KR100267149B1 (ko)	2000-09-15	사이클로스포린을 함유하는 약학 조성물
DD283404A5 (de)	1990-10-10	Verfahren zur herstellung von ciclosporin in nichtsolvatisiertr orthonombischer kristallform

Legal Events

Date	Code	Title	Description
1997-05-15	PFA	Name/firm changed	Owner name: SANDOZ AG TRANSFER- NOVARTIS AG
2010-02-26	PL	Patent ceased